Skip to main content

Articles

Page 3 of 64

  1. Among digestive tract tumours, pancreatic ductal adenocarcinoma (PDAC) shows the highest mortality trend. Moreover, although PDAC metastasis remains a leading cause of cancer-related deaths, the biological mec...

    Authors: Zhongjie Zhao, Wenbo Yang, Rui Kong, Yangyang Zhang, Le Li, Zengfu Song, Hongze Chen, Yan Luo, Tao Zhang, Chundong Cheng, Guanqun Li, Danxi Liu, Xinglong Geng, Hua Chen, Yongwei Wang, Shangha Pan…
    Citation: Molecular Cancer 2023 22:152
  2. Bladder cancer (BCa) is the fourth most common malignant tumor with a poor prognosis worldwide. Further exploration and research are needed to unmask the underlying roles and molecular mechanisms of circular R...

    Authors: Bo Xie, Juntao Lin, Xianwu Chen, Xuejian Zhou, Yan Zhang, Mengjing Fan, Jiayong Xiang, Ning He, Zhenghui Hu and Feifan Wang
    Citation: Molecular Cancer 2023 22:151
  3. Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (...

    Authors: Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak and Katarzyna Magiera-Mularz
    Citation: Molecular Cancer 2023 22:150
  4. The term “metastatic cascade” defines a process whereby few tumor cells complete a sequence of steps to leave the primary tumor to reach one or more sites elsewhere in the body, usually through the bloodstream...

    Authors: Veronica Marabitti, Ignazio Caruana and Francesca Nazio
    Citation: Molecular Cancer 2023 22:149
  5. Neutrophils, the most prevalent innate immune cells in humans, have garnered significant attention in recent years due to their involvement in cancer progression. This comprehensive review aimed to elucidate t...

    Authors: Siyao Liu, Wenchuan Wu, Yueshan Du, Hanlin Yin, Qiangda Chen, Weisheng Yu, Wenquan Wang, Jun Yu, Liang Liu, Wenhui Lou and Ning Pu
    Citation: Molecular Cancer 2023 22:148
  6. Gastric adenocarcinoma (GAC) is a lethal disease characterized by genomic and clinical heterogeneity. By integrating 8 previously established genomic signatures for GAC subtypes, we identified 6 clinically and...

    Authors: Yun Seong Jeong, Young-Gyu Eun, Sung Hwan Lee, Sang-Hee Kang, Sun Young Yim, Eui Hyun Kim, Joo Kyung Noh, Bo Hwa Sohn, Seon Rang Woo, Moonkyoo Kong, Deok Hwa Nam, Hee-Jin Jang, Hyun-Sung Lee, Shumei Song, Sang Cheul Oh, Jeeyun Lee…
    Citation: Molecular Cancer 2023 22:147
  7. Multidrug resistance renders treatment failure in a large proportion of head and neck squamous cell carcinoma (HNSCC) patients that require multimodal therapy involving chemotherapy in conjunction with surgery...

    Authors: Neha Khera, Asvika Soodhalaagunta Rajkumar, Khlood Abdulkader M Alkurdi, Zhiao Liu, Hong Ma, Ahmad Waseem and Muy-Teck Teh
    Citation: Molecular Cancer 2023 22:146
  8. Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor...

    Authors: Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu and Xi Gu
    Citation: Molecular Cancer 2023 22:145

    The Correction to this article has been published in Molecular Cancer 2023 22:154

  9. Authors: Zhenlong Yu, Wei Guo, Xiaochi Ma, Baojing Zhang, Peipei Dong, Lin Huang, Xiuli Wang, Chao Wang, Xiaokui Huo, Wendan Yu, Canhui Yi, Yao Xiao, Wenjing Yang, Yu Qin, Yuhui Yuan, Songshu Meng…
    Citation: Molecular Cancer 2023 22:144

    The original article was published in Molecular Cancer 2014 13:203

  10. Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the developme...

    Authors: Qin Yu, Wenhao Fu, Yutang Fu, Wenjing Ye, Huiqiong Yan, Zecheng Yu, Ruirui Li, Yili Cai, Yuxin Chen, Lingyun Wang, Xianqiao Wei, Yangkun Chen, Yuheng Zhang, Huazhong Ying, Furong Tang, Fangwei Dai…
    Citation: Molecular Cancer 2023 22:143
  11. Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade ...

    Authors: Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocío Granda-Díaz, Alejandra Martínez-Pérez, Candelaria Aguilar-García, Juan P. Rodrigo, Juana M. García-Pedrero and Segundo Gonzalez
    Citation: Molecular Cancer 2023 22:142
  12. Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid ...

    Authors: Jiangping Li, Zhiwen Xiao, Donghui Wang, Lei Jia, Shihong Nie, Xingda Zeng and Wei Hu
    Citation: Molecular Cancer 2023 22:141
  13. Authors: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun…
    Citation: Molecular Cancer 2023 22:139

    The original article was published in Molecular Cancer 2020 19:90

  14. The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to...

    Authors: Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, Daniel B. L. Teh…
    Citation: Molecular Cancer 2023 22:138
  15. Glycolytic reprogramming is one of the most important features of cancer and plays an integral role in the progression of cancer. In cancer cells, changes in glucose metabolism meet the needs of self-prolifera...

    Authors: Shi-Wei Yue, Hai-Ling Liu, Hong-Fei Su, Chu Luo, Hui-Fang Liang, Bi-Xiang Zhang and Wei Zhang
    Citation: Molecular Cancer 2023 22:137
  16. New therapies are urgently needed in melanoma, particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors. To uncover novel potentiators of T cell anti-tumor immunity, we carri...

    Authors: Paweł Stachura, Wei Liu, Haifeng C. Xu, Agnès Wlodarczyk, Olivia Stencel, Piyush Pandey, Melina Vogt, Sanil Bhatia, Daniel Picard, Marc Remke, Karl S. Lang, Dieter Häussinger, Bernhard Homey, Philipp A. Lang, Arndt Borkhardt and Aleksandra A. Pandyra
    Citation: Molecular Cancer 2023 22:136
  17. Authors: Hyunbin D. Huh, Yujin Sub, Jongwook Oh, Ye Eun Kim, Ju Young Lee, Hwa‑Ryeon Kim, Soyeon Lee, Hannah Lee, Sehyung Pak, Sebastian E. Amos, Danielle Vahala, Jae Hyung Park, Ji Eun Shin, So Yeon Park, Han Sang Kim, Young Hoon Roh…
    Citation: Molecular Cancer 2023 22:135

    The original article was published in Molecular Cancer 2023 22:63

  18. Authors: Jinpeng Du, Tian Lan, Haotian Liao, Xuping Feng, Xing Chen, Wenwei Liao, Guimin Hou, Lin Xu, Qingbo Feng, Kunlin Xie, Mingheng Liao, Xiangzheng Chen, Jiwei Huang, Kefei Yuan and Yong Zeng
    Citation: Molecular Cancer 2023 22:134

    The original article was published in Molecular Cancer 2022 21:18

  19. Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood. PTEN is one of the mo...

    Authors: Jan Pencik, Cecile Philippe, Michaela Schlederer, Emine Atas, Matteo Pecoraro, Sandra Grund-Gröschke, Wen (Jess) Li, Amanda Tracz, Isabel Heidegger, Sabine Lagger, Karolína Trachtová, Monika Oberhuber, Ellen Heitzer, Osman Aksoy, Heidi A. Neubauer, Bettina Wingelhofer…
    Citation: Molecular Cancer 2023 22:133
  20. Chimeric antigen receptor (CAR) -T cell therapy is an efficient therapeutic strategy for specific hematologic malignancies. However, positive outcomes of this novel therapy in treating solid tumors are curtail...

    Authors: Jian Chen, Tianchuan Zhu, Guanmin Jiang, Qi Zeng, Zhijian Li and Xi Huang
    Citation: Molecular Cancer 2023 22:131
  21. The reversible oxidation-reduction homeostasis mechanism functions as a specific signal transduction system, eliciting related physiological responses. Disruptions to redox homeostasis can have negative conseq...

    Authors: Yuqing Ren, Ruizhi Wang, Siyuan Weng, Hui Xu, Yuyuan Zhang, Shuang Chen, Shutong Liu, Yuhao Ba, Zhaokai Zhou, Peng Luo, Quan Cheng, Qin Dang, Zaoqu Liu and Xinwei Han
    Citation: Molecular Cancer 2023 22:130
  22. This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4 (hrBMP4) – an inhibitory regulator of cancer stem ...

    Authors: Eelke M. Bos, Elena Binda, Iris S.C. Verploegh, Eva Wembacher, Daphna Hoefnagel, Rutger K. Balvers, Anne L. Korporaal, Andrea Conidi, Esther A. H. Warnert, Nadia Trivieri, Alberto Visioli, Paola Zaccarini, Laura Caiola, Rogier van Wijck, Peter van der Spek, Danny Huylebroeck…
    Citation: Molecular Cancer 2023 22:129
  23. Protein regulator of cytokinesis 1 (PRC1) is involved in cytokinesis. Growing evidence suggests the association of PRC1 with multiple cancers. Here, we unveil that, in 28 cancer types, PRC1 is higher expressed...

    Authors: Sijing Li, Omar Motiño, Flavia Lambertucci, Isabelle Martins, Li Sun and Guido Kroemer
    Citation: Molecular Cancer 2023 22:128
  24. Approximately 15% of adult GIST patients harbor tumors that are wild-type for KIT and PDGFRα genes (KP-wtGIST). These tumors usually have SDH deficiencies, exhibit a more indolent behavior and are resistant to...

    Authors: Javier Martin-Broto, Claudia Valverde, Nadia Hindi, Bruno Vincenzi, Javier Martinez-Trufero, Giovanni Grignani, Antoine Italiano, Javier Lavernia, Ana Vallejo, Paolo Dei Tos, Francois Le Loarer, Ricardo Gonzalez-Campora, Rafael Ramos, Diana Hernández-Jover, Antonio Gutierrez, Cesar Serrano…
    Citation: Molecular Cancer 2023 22:127
  25. Children with birth defects (BD) express distinct clinical features that often have various medical consequences, one of which is predisposition to the development of cancers. Identification of the underlying ...

    Authors: Yichuan Liu, Hui-Qi Qu, Xiao Chang, Frank D Mentch, Haijun Qiu, Xiang Wang, Amir Hossein Saeidian, Deborah Watson, Joseph Glessner and Hakon Hakonarson
    Citation: Molecular Cancer 2023 22:126
  26. Hairy cell leukemia (HCL) is a B-lymphoma induced by BRAF(V600E) mutation. However, introducing BRAF(V600E) in B-lymphocytes fails to induce hematological malignancy, suggesting that BRAF(V600E) needs concurre...

    Authors: Jiajun Yap, Jimin Yuan, Wan Hwa Ng, Gao Bin Chen, Yuen Rong M. Sim, Kah Chun Goh, Joey Teo, Trixie Y. H. Lim, Shee Min Goay, Jia Hao Jackie Teo, Zhentang Lao, Paula Lam, Kanaga Sabapathy and Jiancheng Hu
    Citation: Molecular Cancer 2023 22:125
  27. Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-...

    Authors: Linlin Zhang, Liuchun Wang, Jingya Wang, Jinliang Chen, Zhaoting Meng, Zhujun Liu, Xiangli Jiang, Xinyue Wang, Chun Huang, Peng Chen, Yan Liang, Richeng Jiang, Jing Wang, Diansheng Zhong, Yanhong Shang, Yan Zhang…
    Citation: Molecular Cancer 2023 22:124
  28. Lung cancer is the leading cause of cancer-related deaths worldwide. Long non-coding RNAs (lncRNAs) have emerged as key regulators of cancer development and progression, and as promising biomarkers for the dia...

    Authors: Qiurong Yang, Maoye Wang, Jing Xu, Dan Yu, Yixin Li, Yanke Chen, Xiaoxin Zhang, Jiahui Zhang, Jianmei Gu and Xu Zhang
    Citation: Molecular Cancer 2023 22:122
  29. Non-small cell lung cancer is a very poor prognosis disease. Molecular analyses have highlighted several genetic alterations which may be targeted by specific therapies. In clinical practice, progression-free ...

    Authors: Lorraine Dalens, Julie Niogret, Corentin Richard, Sandy Chevrier, Pascal Foucher, Bruno Coudert, Aurélie Lagrange, Laure Favier, Virginie Westeel, Stefano Kim, Olivier Adotevi, Caroline Chapusot, Laurent Martin, Laurent Arnould, Courèche-Guillaume Kaderbhai and Romain Boidot
    Citation: Molecular Cancer 2023 22:120
  30. Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome d...

    Authors: Raquel García-Vílchez, Ana M. Añazco-Guenkova, Sabine Dietmann, Judith López, Virginia Morón-Calvente, Silvia D’Ambrosi, Paz Nombela, Kepa Zamacola, Isabel Mendizabal, Saioa García-Longarte, Amaia Zabala-Letona, Ianire Astobiza, Sonia Fernández, Alejandro Paniagua, Borja Miguel-López, Virginie Marchand…
    Citation: Molecular Cancer 2023 22:119
  31. The encapsulation of circular RNAs (circRNAs) into extracellular vesicles (EVs) enables their involvement in intercellular communication and exerts an influence on the malignant advancement of various tumors. ...

    Authors: Tao He, Qiansheng Zhang, Peng Xu, Wen Tao, Fuyang Lin, Renfei Liu, Mingzhao Li, Xiaolu Duan, Chao Cai, Di Gu, Guohua Zeng and Yongda Liu
    Citation: Molecular Cancer 2023 22:117
  32. Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of...

    Authors: F Torricelli, B Donati, F Reggiani, V Manicardi, S Piana, R Valli, F Lococo and Alessia Ciarrocchi
    Citation: Molecular Cancer 2023 22:114
  33. Osteosarcoma (OS) is the most prevalent orthopedic malignancy with a dismal prognosis. The high iron absorption rate in OS cells of patients suggests that ferroptosis may be related to the progression of OS, b...

    Authors: Mingyang Jiang, Yiji Jike, Kaicheng Liu, Fu Gan, Ke Zhang, Mingjing Xie, Junlei Zhang, Chuanliang Chen, Xiaochong Zou, Xiaohong Jiang, Yongheng Dai, Weikui Chen, Yue Qiu and Zhandong Bo
    Citation: Molecular Cancer 2023 22:113
  34. The mechanistic/mammalian target of rapamycin (mTOR), a protein discovered in 1991, integrates a complex pathway with a key role in maintaining cellular homeostasis. By comprising two functionally distinct com...

    Authors: A Marques-Ramos and R Cervantes
    Citation: Molecular Cancer 2023 22:112
  35. The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatme...

    Authors: Aatiya Ahmad, Parvez Khan, Asad Ur Rehman, Surinder Kumar Batra and Mohd Wasim Nasser
    Citation: Molecular Cancer 2023 22:111
  36. Drugs targeting the spindle assembly checkpoint (SAC), such as inhibitors of Aurora kinase B (AURKB) and dual specific protein kinase TTK, are in different stages of clinical development. However, cell respons...

    Authors: Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Nicolas Floc’h, Elizabeth Martínez-Pérez, Matthew J. Martin, Paul D. Smith, Ivana Sullivan, Mikkel G. Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu…
    Citation: Molecular Cancer 2023 22:110
  37. Authors: Yongyan Wu, Yuliang Zhang, Xiwang Zheng, Fengsheng Dai, Yan Lu, Li Dai, Min Niu, Huina Guo, Wenqi Li, Xuting Xue, Yunfeng Bo, Yujia Guo, Jiangbo Qin, Yixiao Qin, Hongliang Liu, Yu Zhang…
    Citation: Molecular Cancer 2023 22:109

    The original article was published in Molecular Cancer 2020 19:99

  38. The reintegration of excised signal joints resulting from human V(D)J recombination was described as a potent source of genomic instability in human lymphoid cancers. However, such molecular events have not be...

    Authors: Estelle Balducci, Thomas Steimlé, Charlotte Smith, Patrick Villarese, Mélanie Feroul, Dominique Payet-Bornet, Sophie Kaltenbach, Lucile Couronné, Ludovic Lhermitte, Aurore Touzart, Marie-Emilie Dourthe, Mathieu Simonin, André Baruchel, Hervé Dombret, Norbert Ifrah, Nicolas Boissel…
    Citation: Molecular Cancer 2023 22:108
  39. Acute leukemias represent deadly malignancies that require better treatment. As a challenge, treatment is counteracted by a microenvironment protecting dormant leukemia stem cells.

    Authors: Ehsan Bahrami, Jan Philipp Schmid, Vindi Jurinovic, Martin Becker, Anna-Katharina Wirth, Romina Ludwig, Sophie Kreissig, Tania Vanessa Duque Angel, Diana Amend, Katharina Hunt, Rupert Öllinger, Roland Rad, Joris Maximilian Frenz, Maria Solovey, Frank Ziemann, Matthias Mann…
    Citation: Molecular Cancer 2023 22:107
  40. Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology a...

    Authors: Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha, Zhe-Sheng Chen, Ankush Kumar, Vishakha, Tapan Behl, Saurabh Kumar Jha and Hailin Tang
    Citation: Molecular Cancer 2023 22:105
  41. The treatment of Triple-negative breast cancer (TNBC) has always been challenging due to its heterogeneity and the absence of well-defined molecular targets. The present study aims to elucidate the role of pro...

    Authors: Runjie Song, Peilan Guo, Xin Ren, Lijun Zhou, Peng Li, Nafis A Rahman, Sławomir Wołczyński, Xiru Li, Yanjun Zhang, Mei Liu, Jiali Liu and Xiangdong Li
    Citation: Molecular Cancer 2023 22:104
  42. Tyrosine kinase inhibitors (TKIs) that specifically target mutational points in the EGFR gene have significantly reduced suffering and provided greater relief to patients with lung adenocarcinoma (LUAD). The t...

    Authors: Kai Li, Zi-Yang Peng, Rui Wang, Xiang Li, Ning Du, Da-Peng Liu, Jia Zhang, Yun-Feng Zhang, Lei Ma, Ye Sun, Shou-Ching Tang, Hong Ren, Yi-Ping Yang and Xin Sun
    Citation: Molecular Cancer 2023 22:103

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    76 days submission to accept (Median)

    2022 Usage 
    3,062,329 downloads
    4,920 Altmetric mentions